针对新兴δ冠状病毒的广泛中和抗体的分离与逃逸图谱分析
Isolation and escape mapping of broadly neutralizing antibodies against emerging delta-coronaviruses.
作者信息
Rexhepaj Megi, Asarnow Daniel, Perruzza Lisa, Park Young-Jun, Guarino Barbara, Mccallum Mathew, Culap Katja, Saliba Christian, Leoni Giada, Balmelli Alessio, Yoshiyama Courtney N, Dickinson Miles S, Quispe Joel, Brown Jack T, Tortorici M Alejandra, Sprouse Kaitlin R, Taylor Ashley L, Corti Davide, Starr Tyler N, Benigni Fabio, Veesler David
机构信息
Department of Biochemistry, University of Washington, Seattle, WA, USA.
Humabs Biomed SA, a Subsidiary of Vir. Biotechnology, 6500 Bellinzona, Switzerland.
出版信息
Immunity. 2024 Dec 10;57(12):2914-2927.e7. doi: 10.1016/j.immuni.2024.10.001. Epub 2024 Nov 1.
Porcine delta-coronavirus (PDCoV) spillovers were recently detected in febrile children, underscoring the recurrent zoonoses of divergent CoVs. To date, no vaccines or specific therapeutics are approved for use in humans against PDCoV. To prepare for possible future PDCoV epidemics, we isolated PDCoV spike (S)-directed monoclonal antibodies (mAbs) from humanized mice and found that two, designated PD33 and PD41, broadly neutralized a panel of PDCoV variants. Cryoelectron microscopy (cryo-EM) structures of PD33 and PD41 in complex with the S receptor-binding domain (RBD) and ectodomain trimer revealed the epitopes recognized by these mAbs, rationalizing their broad inhibitory activity. We show that both mAbs competitively interfere with host aminopeptidase N binding to neutralize PDCoV and used deep-mutational scanning epitope mapping to associate RBD antigenic sites with mAb-mediated neutralization potency. Our results indicate a PD33-PD41 mAb cocktail may heighten the barrier to escape. PD33 and PD41 are candidates for clinical advancement against future PDCoV outbreaks.
最近在发热儿童中检测到猪δ冠状病毒(PDCoV)溢出,这凸显了不同冠状病毒反复出现的人畜共患病情况。迄今为止,尚无针对人类的抗PDCoV疫苗或特定治疗方法获批使用。为应对未来可能出现的PDCoV疫情,我们从人源化小鼠中分离出了针对PDCoV刺突(S)蛋白的单克隆抗体(mAb),并发现其中两种名为PD33和PD41的抗体能够广泛中和一组PDCoV变体。PD33和PD41与S受体结合域(RBD)及胞外域三聚体复合物的冷冻电子显微镜(cryo-EM)结构揭示了这些单克隆抗体识别的表位,解释了它们广泛的抑制活性。我们表明,这两种单克隆抗体均通过竞争性干扰宿主氨肽酶N的结合来中和PDCoV,并利用深度突变扫描表位作图将RBD抗原位点与单克隆抗体介导的中和效力相关联。我们的结果表明,PD33-PD41单克隆抗体鸡尾酒可能会提高病毒逃逸的障碍。PD33和PD41是针对未来PDCoV疫情进行临床推进的候选药物。
相似文献
Proc Natl Acad Sci U S A. 2023-6-6